sacituzumab govitecan-hziy

An exploratory analysis in the ASCENT study showed improved survival with Gilead's antibody-drug conjugate regardless of patients' biomarker status.

Trodelvy's clinical development in China, led by Everest Medicines, follows the agent's US accelerated approval in April for triple-negative breast cancer. 

The research showed that atezolizumab plus nab-paclitaxel provided survival benefits, as did an antibody-drug conjugate that was recently approved by the FDA.